PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1005
- Registration Number
- NCT00143364
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2000
- Registration Number
- NCT00143286
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 730
- Registration Number
- NCT00143325
- Locations
- 🇬🇧
Pfizer Investigational Site, Nottingham, United Kingdom
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00143143
- Locations
Pfizer Investigational Site
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 298
- Registration Number
- NCT00143390
- Locations
- 🇯🇵
Pfizer Investigational Site, Shizuoka, Japan
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 321
- Registration Number
- NCT00143403
- Locations
- 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00142103
- Locations
- 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00143104
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 173
- Registration Number
- NCT00143247
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 485
- Registration Number
- NCT00143455
- Locations
- 🇨🇳
Pfizer Investigational Site, Taoyuan, Taiwan
© Copyright 2024. All Rights Reserved by MedPath